This glossary provides brief explanations of terms used in the Ontario Public Drug Programs web pages. To access a term definition, select the appropriate letter from the alphabet below.
| National Pharmaceutical Strategy (NPS) |
In September 2004, Canada’s First Ministers directed their Health Ministers to establish a Ministerial Task Force to develop a National Pharmaceuticals Strategy, as part of the 2004 10-Year Plan to Strengthen Health Care. The five priorities of the Strategy are: Real World Safety and Effectiveness, Expensive Drugs for Rare Diseases.
Drug Pricing and Purchasing Strategies (bulk purchasing and potential negotiations), Catastrophic Drug Coverage, and Common Formulary (expansion of CDR).
|
| New Chemical Entity (NCE) |
A compound that has not previously been described in the literature or marketed in Canada, or which Health Canada has not previously approved for sale in Canada.
|
| NOC or NOC/c |
See Notice of Compliance or Notice of Compliance with Conditions
|
| Non-inferiority study |
Non-inferiority studies are designed to show that the effect of a new treatment is not worse than that of another treatment (e.g. an established standard) by more than a specified margin.
Non-inferiority studies differ from superiority studies, which assess whether one treatment is better than another, and equivalence studies (typically bioequivalence studies), which assess whether two treatments are equal within a specified margin. |
| Notice of Compliance or Notice of Compliance with Conditions |
The notice that Health Canada provides to manufacturers authorizing them to market a drug, sometimes under specific conditions.
|
| NPS |
See National Pharmaceutical Strategy |
Text Only Version
